Indigo Diabetic issues Company Update

Press Launch

Indigo Diabetes Small business Update

Shine medical demo enrolment progressing very well next beneficial outcomes from the GLOW early feasibility trialSeveral essential senior appointments produced in Europe and the US, reflecting the development and evolution from an early phase to a development phase organisation with scientific evidence of idea

BELGIUM – Ghent, 4 January 2023 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a groundbreaking developer of Ongoing Metabolite Monitoring (CMM™) units utilising proprietary nanophotonics technological know-how, right now offers an update on latest and ongoing company activities.

Indigo is establishing a fully implantable CMM program for individuals living with diabetic issues to accessibility exact facts on their glucose, ketones and lactate ranges. The CMM sensor is inserted subcutaneously, avoiding the require for people today with diabetic issues to don an exterior product on their entire body. It is made to give men and women dwelling with diabetic issues and their caregivers instant access to the augmented metabolic information they need to have to superior handle their diabetes and improve therapeutic selection-creating.

Medical analyze development
In September 2022, Indigo declared the enrolment of the initially participant in the Glow medical trial at the Antwerp University Healthcare facility, Belgium. Glow is designed to assess the for a longer period-expression steadiness of Indigo’s continual multi-metabolite (‘CMM’) gadget. This represented the 1st of up to 15 participants to be recruited in the demo throughout Belgium, France and Slovenia, the latter two websites of which are owing to start off enrolment in Q1 2023.

The GLOW medical trial was a potential, one-center early feasibility review conducted at the Antwerp College Medical center, Belgium to consider the security of Indigo’s CMM sensor and its limited-expression integration into the tissue. Knowledge was gathered from the seven demo participants (three wholesome topics, and 4 topics with style 1 diabetes) and the benefits have assisted development the improvement of the unit to enable actual-time, steady measurement of glucose, ketone, and lactate stages in grown ups with diabetic issues. The complete GLOW trial final results have not long ago been submitted to a peer reviewed journal.

In the direction of the close of 2022 Indigo obtained the ISO 13485:2016 medical recertification from TüV SUD for the provision of its structure and progress of biomarker sensing equipment and expert services. This achievement is a substantial milestone for Indigo highlighting the suitability of the Company’s Excellent Management Procedure and its determination to good quality. ISO 13485:2016 is an internationally recognised quality typical particular to the health-related machine market that ensures the top quality of medical devices.

Essential appointments
A selection of senior hires have been designed all through 2022 getting the whole headcount to 45, reflecting the ongoing growth of the business and evolution from an early stage to a improvement phase organisation with medical proof of strategy.

In Oct, Indigo appointed Peter Devlin as President of Indigo Health care US Inc, developing its presence in the US, a market that it has recognized as owning sizeable opportunity for its CMM devices. Peter, who is based in Boston, is handling and overseeing Indigo Medical’s pursuits. His concentration is on accelerating merchandise development for the Company’s CMM units, driving business enterprise progress, and facilitating talent acquisition in the US.

An additional vital employ was made in Might, with the appointment of Emmet Lydon as Main Running Officer. Emmet provides much more than 30 years of knowledge doing work as a senior chief working in a multinational existence sciences setting with considerable practical experience in Asia, North The usa and Europe.

In addition, Indigo appointed Michael Malecha as VP, Electronic. Michael now prospects the software package crew, establishing electronic approaches for Indigo’s CMM product.

Dr. Danaë Delbeke, CEO, Inventor and Co-founder of Indigo Diabetic issues, commented: “2022 was a great year for the staff at Indigo the place we reached a variety of key milestones including the enrollment of the very first participant in the Shine trial and creating our existence in the US. We glance forward to the 12 months forward where we carry on to do the job in the direction of our mission to give an ground breaking, correct and effortless monitoring option to mild up the lifestyle of millions of individuals living with diabetic issues.”

Dr. Danaë Delbeke, CEO and Peter Devlin, President of Indigo Diabetes will be visiting San Francisco in January at the time of the 41st JP Morgan Healthcare conference and are presently arranging conferences with investors and associates. Make sure you call the firm instantly if you would like to set up a conference.

– Finishes –


Indigo Diabetes N.V.
Dr Danaë Delbeke, CEO

Consilium Strategic Communications
Ashley Tapp, Alexandra Harrison
Tel: +44 ()20 3709 5700

About Indigo Diabetic issues N.V.
Indigo Diabetic issues N.V. (Indigo) is a pioneering developer of clinical devices that utilise proprietary nanophotonics know-how. Indigo was established by Danaë Delbeke and her staff in 2016. Currently Indigo is establishing the world’s very first subcutaneously inserted sensor for men and women residing with diabetes to address their will need for continuous accurate glucose, ketone and lactate monitoring with almost nothing worn on the human body. Indigo makes use of ground-breaking photonics technological know-how to completely transform diabetic issues administration. Indigo is centered in Ghent, Belgium. Find out a lot more at

About Indigo Diabetes’s CMM™ sensor
Indigo Diabetes’s CMM™ sensor is the world’s first, subcutaneously inserted evanescent area sensor to evaluate several metabolites in vivo at the same time and repeatedly. The inert, miniature built-in silicon photonics chip steps the absorption of gentle in interstitial fluid to quantify the concentration of a broad selection of metabolites concurrently devoid of the use of enzymes or fluorophores. The moment inserted underneath the skin the CMM sensor is invisible to the bare eye and will connect securely and wirelessly to cell gadgets to exhibit and seize the focus profiles of the metabolites for the consumer. A rechargeable sensor battery powers the measurements. It is envisioned that the sensor will have a life span up to 2 yrs. Preclinical scientific tests have properly shown proof of idea with promising precision with GLOW early feasibility study effects delivering additional validation.

News Viber